Davis AI | $5,500,000 | (May 8, 2026)
Balcony | $12,700,000 | (May 8, 2026)
Jetty | $2,000,000 | (May 8, 2026)
Receptor Life Sciences, Inc.
United States
- Seattle, Washington
- 07/04/2022
- Series A
- $9,700,000
Receptor Life Sciences combines proven drug delivery technologies, compelling therapeutic candidates, and traditional drug development research practices to pursue a robust range of prescription drug treatments for CNS indications.
The delivery technologies, used in both oral and inhaled FDA-approved prescription drug products, represent a validated, strategic approach to overcoming traditional challenges of cannabinoid medicine. Receptor’s patented product candidates hold the potential to provide prescription treatments for a range of unmet medical needs, including anxiety and agitation in autism.
More information is at www.ReceptorLife.com.
- Industry Pharmaceutical Manufacturing
- Website https://receptorlife.com/
- LinkedIn https://www.linkedin.com/company/receptor-life-sciences-inc./
Related People
Mark TheeuwesFounder
United States -
Greater Philadelphia
Experienced Pharmaceutical Executive with a demonstrated history of working in all aspects of Clinical and Commercial Execution.
ParcelBio | $13,000,000 | (May 8, 2026)
Jesse & Ben's | $10,000,000 | (May 8, 2026)
SageOx | $15,000,000 | (May 8, 2026)
CodeWords | $9,000,000 | (May 8, 2026)
Ethos | $22,750,000 | (May 8, 2026)
illoca | $13,000,000 | (May 8, 2026)
Lithosquare | $25,000,000 | (May 8, 2026)
Jurisphere.ai | $2,200,000 | (May 8, 2026)
OpsMill | $14,000,000 | (May 8, 2026)